Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S5.54
P/E—
Fwd P/E13.80
PEG2.14
52W— – —
RSI—
Target$157.15 (+18.4%)
Beta0.34
Div2.37%
Loading chart…
RSI (14)
Loading patterns…
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 53
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
1Bullish
1Bearish
0Neutral
▲ Bull Flag — Breakout after +12% pole — bullish continuation
▼ Double Top — Two peaks ~$139.32 — bearish reversal confirmed
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$157.15
+18.4% upside
Low $120
—
High $180
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| Barclays | Equal-Weight | — | ↔ Maintain | 2026-07-29 |
| Morgan Stanley | Overweight | — | ↔ Maintain | 2026-07-27 |
| Leerink Partners | Market Perform | Outperform → Market Perform | ▼ Downgrade | 2026-07-21 |
| RBC Capital | Sector Perform | — | ↔ Maintain | 2026-07-07 |
| Truist Securities | Buy | — | ↔ Maintain | 2026-07-07 |
| Cantor Fitzgerald | Overweight | — | ↔ Reiterate | 2026-07-06 |
| HSBC | Buy | Hold → Buy | ▲ Upgrade | 2026-07-06 |
| Maxim Group | Buy | Hold → Buy | ▲ Upgrade | 2026-05-20 |
| Citigroup | Buy | — | ↔ Maintain | 2026-04-13 |
| Jefferies | Buy | — | ● Initiate | 2026-03-10 |
| Needham | Buy | — | ↔ Reiterate | 2026-02-23 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2026-02-11 |
| Scotiabank | Sector Outperform | — | ↔ Maintain | 2026-02-11 |
| UBS | Buy | — | ↔ Maintain | 2026-01-26 |
| JP Morgan | Overweight | — | ↔ Maintain | 2025-10-31 |
Barclays
2026-07-29
Equal-Weight
↔ Maintain
Morgan Stanley
2026-07-27
Overweight
↔ Maintain
Leerink Partners
2026-07-21
Market Perform
(from Outperform)
▼ Downgrade
RBC Capital
2026-07-07
Sector Perform
↔ Maintain
Truist Securities
2026-07-07
Buy
↔ Maintain
Cantor Fitzgerald
2026-07-06
Overweight
↔ Reiterate
HSBC
2026-07-06
Buy
(from Hold)
▲ Upgrade
Maxim Group
2026-05-20
Buy
(from Hold)
▲ Upgrade
Citigroup
2026-04-13
Buy
↔ Maintain
Jefferies
2026-03-10
Buy
● Initiate
Needham
2026-02-23
Buy
↔ Reiterate
Wells Fargo
2026-02-11
Overweight
↔ Maintain
Scotiabank
2026-02-11
Sector Outperform
↔ Maintain
UBS
2026-01-26
Buy
↔ Maintain
JP Morgan
2025-10-31
Overweight
↔ Maintain
Profitability
Gross Margin
79.37%TTM
Op. Margin
39.28%TTM
ROE
43.36%TTM
Rev. Growth
4.40%YoY
Free Cash Flow
7.93BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
94.64MRQ
Current Ratio
1.97MRQ
Cash
9.82BMRQ
Total Debt
22.17BMRQ
Net Debt
—MRQ
Income
Div. Yield
2.37%TTM
Annual Rate
3.28Fwd
Payout Ratio
43.40%TTM
Dividend History
Payout Ratio (TTM): 43.40%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-06-15 | $0.8200 | 0.66% |
| 2026-03-13 | $0.8200 | 0.57% |
| 2025-12-15 | $0.7900 | 0.67% |
| 2025-09-15 | $0.7900 | 0.71% |
| 2025-06-13 | $0.7900 | 0.74% |
| 2025-03-14 | $0.7900 | 0.73% |
| 2024-12-13 | $0.7700 | 0.87% |
| 2024-09-13 | $0.7700 | 0.98% |
| 2024-06-14 | $0.7700 | 1.25% |
| 2024-03-14 | $0.7700 | 1.11% |
| 2023-12-14 | $0.7500 | 0.99% |
| 2023-09-14 | $0.7500 | 1.06% |
| 2023-06-14 | $0.7500 | 1.06% |
| 2023-03-14 | $0.7500 | 1.05% |
| 2022-12-14 | $0.7300 | 0.93% |
| 2022-09-14 | $0.7300 | 1.27% |
| 2022-06-14 | $0.7300 | 1.45% |
| 2022-03-14 | $0.7300 | 1.46% |
| 2021-12-14 | $0.7100 | 1.18% |
| 2021-09-14 | $0.7100 | 1.20% |
| 2021-06-14 | $0.7100 | 1.25% |
| 2021-03-12 | $0.7100 | 1.40% |
| 2020-12-14 | $0.6800 | 1.39% |
| 2020-09-14 | $0.6800 | 1.27% |
| 2020-06-11 | $0.6800 | 1.17% |
| 2020-03-12 | $0.6800 | 1.25% |
| 2019-12-12 | $0.6300 | 1.19% |
| 2019-09-12 | $0.6300 | 1.22% |
| 2019-06-13 | $0.6300 | 1.22% |
| 2019-03-14 | $0.6300 | 1.28% |
| 2018-12-13 | $0.5700 | 1.12% |
| 2018-09-13 | $0.5700 | 1.03% |
| 2018-06-14 | $0.5700 | 1.08% |
| 2018-03-15 | $0.5700 | 0.97% |
| 2017-12-14 | $0.5200 | 0.96% |
| 2017-09-14 | $0.5200 | 0.87% |
| 2017-06-14 | $0.5200 | 1.11% |
| 2017-03-14 | $0.5200 | 1.07% |
| 2016-12-13 | $0.4700 | 0.88% |
| 2016-09-14 | $0.4700 | 0.86% |
How GILD Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 164.79B |
| Enterprise Value | 177.07B |
| Trailing P/E | 18.28 |
| Forward P/E | 13.80 |
| PEG Ratio (5yr) | 2.14 |
| Price/Sales (ttm) | 5.54 |
| Price/Book (mrq) | 7.01 |
| EV/Revenue | 5.96 |
| EV/EBITDA | 12.01 |
Share Statistics
| Avg Vol (3m) | 7.57M |
| Shares Outstanding | 1.24B |
| Float | 1.24B |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 92.13% |
| Short Ratio | 3.06 |
| Short % of Float | 2.04% |
Profitability
| Gross Margin | 79.37% |
| Operating Margin (ttm) | 39.28% |
| Profit Margin | 30.99% |
| Return on Assets (ttm) | 13.29% |
| Return on Equity (ttm) | 43.36% |
Income Statement
| Revenue (ttm) | 29.74B |
| Revenue Growth (yoy) | 4.40% |
| Gross Profit (ttm) | 23.60B |
| EBITDA | 14.74B |
| Net Income (ttm) | 9.22B |
| Diluted EPS (ttm) | 7.26 |
| EPS Growth (yoy) | 54.80% |
Balance Sheet
| Total Cash (mrq) | 9.82B |
| Total Debt (mrq) | 22.17B |
| Debt / Equity (mrq) | 94.64 |
| Current Ratio (mrq) | 1.97 |
| Book Value / Share | 18.93 |
| Operating CF (ttm) | 10.81B |
| Free Cash Flow (ttm) | 7.93B |
Trading & Dividends
| Beta (5Y) | 0.34 |
| 50-Day MA | 129.65 |
| 200-Day MA | 131.56 |
| Fwd Dividend Yield | 244.00% |
| Payout Ratio | 43.40% |
Ownership Breakdown
Institutional 92.13%
Insider 0.12%
Public 7.8%
Short Interest
2.04% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in GILD in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-15 | MERCIER JOHANNA | Officer | Sale at price 129.92 per share. | 3,000 | $389,758 |
| 2026-07-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale at price 129.93 per share. | 3,000 | $389,777 |
| 2026-07-01 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale at price 126.09 - 127.08 per share. | 15,000 | $1,894,400 |
| 2026-06-15 | MERCIER JOHANNA | Officer | Sale at price 123.42 - 125.40 per share. | 3,000 | $371,762 |
| 2026-06-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale at price 125.40 per share. | 3,000 | $376,200 |
| 2026-06-10 | CAIN WETTAN KEELEY M | General Counsel | 589 | — | |
| 2026-06-10 | MERCIER JOHANNA | Officer | 2,796 | — | |
| 2026-06-10 | O'DAY DANIEL PATRICK | Chief Executive Officer | 8,779 | — | |
| 2026-06-10 | BERGER DIETMAR P. | Officer | 533 | — | |
| 2026-06-10 | DICKINSON ANDREW D | Chief Financial Officer | 2,796 | — | |
| 2026-06-01 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale at price 131.10 - 132.97 per share. | 15,000 | $1,971,847 |
| 2026-05-15 | MERCIER JOHANNA | Officer | Conversion of Exercise of derivative security at price 66.64 per share. | 25,000 | $1,666,000 |
| 2026-05-15 | MERCIER JOHANNA | Officer | Sale at price 130.29 - 132.75 per share. | 28,000 | $3,676,199 |
| 2026-05-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale at price 132.27 per share. | 3,000 | $396,810 |
| 2026-04-30 | RODRIGUEZ JAVIER | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-30 | HORNING SANDRA | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-30 | BLUESTONE JEFFREY | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-30 | LOVE TED WENDELL | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-30 | BARTON JACQUELINE K | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-30 | WELTERS ANTHONY | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-30 | MANWANI HARISH | Director | Stock Award(Grant) at price 0.00 per share. | 1,146 | — |
| 2026-04-28 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale at price 128.79 - 130.01 per share. | 10,000 | $1,291,608 |
| 2026-04-15 | MERCIER JOHANNA | Officer | Sale at price 140.96 per share. | 3,000 | $422,880 |
| 2026-04-15 | DICKINSON ANDREW D | Chief Financial Officer | Sale at price 140.96 per share. | 3,000 | $422,880 |
| 2026-03-27 | O'DAY DANIEL PATRICK | Chief Executive Officer | Sale at price 136.82 per share. | 10,000 | $1,368,162 |
MERCIER JOHANNA
Officer
Sale at price 129.92 per share.
2026-07-15
3,000 sh
$389,758
DICKINSON ANDREW D
Chief Financial Officer
Sale at price 129.93 per share.
2026-07-15
3,000 sh
$389,777
O'DAY DANIEL PATRICK
Chief Executive Officer
Sale at price 126.09 - 127.08 per share.
2026-07-01
15,000 sh
$1,894,400
MERCIER JOHANNA
Officer
Sale at price 123.42 - 125.40 per share.
2026-06-15
3,000 sh
$371,762
DICKINSON ANDREW D
Chief Financial Officer
Sale at price 125.40 per share.
2026-06-15
3,000 sh
$376,200
CAIN WETTAN KEELEY M
General Counsel
2026-06-10
589 sh
—
MERCIER JOHANNA
Officer
2026-06-10
2,796 sh
—
O'DAY DANIEL PATRICK
Chief Executive Officer
2026-06-10
8,779 sh
—
BERGER DIETMAR P.
Officer
2026-06-10
533 sh
—
DICKINSON ANDREW D
Chief Financial Officer
2026-06-10
2,796 sh
—
O'DAY DANIEL PATRICK
Chief Executive Officer
Sale at price 131.10 - 132.97 per share.
2026-06-01
15,000 sh
$1,971,847
MERCIER JOHANNA
Officer
Conversion of Exercise of derivative security at price 66.64 per share.
2026-05-15
25,000 sh
$1,666,000
MERCIER JOHANNA
Officer
Sale at price 130.29 - 132.75 per share.
2026-05-15
28,000 sh
$3,676,199
DICKINSON ANDREW D
Chief Financial Officer
Sale at price 132.27 per share.
2026-05-15
3,000 sh
$396,810
RODRIGUEZ JAVIER
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
HORNING SANDRA
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
BLUESTONE JEFFREY
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
LOVE TED WENDELL
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
BARTON JACQUELINE K
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
WELTERS ANTHONY
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
MANWANI HARISH
Director
Stock Award(Grant) at price 0.00 per share.
2026-04-30
1,146 sh
—
O'DAY DANIEL PATRICK
Chief Executive Officer
Sale at price 128.79 - 130.01 per share.
2026-04-28
10,000 sh
$1,291,608
MERCIER JOHANNA
Officer
Sale at price 140.96 per share.
2026-04-15
3,000 sh
$422,880
DICKINSON ANDREW D
Chief Financial Officer
Sale at price 140.96 per share.
2026-04-15
3,000 sh
$422,880
O'DAY DANIEL PATRICK
Chief Executive Officer
Sale at price 136.82 per share.
2026-03-27
10,000 sh
$1,368,162